Compare Marriott International Inc (MAR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs 10X Genomics Inc — how do they compare? Marriott International Inc trades at $353.54 (market cap $91.14B), while 10X Genomics Inc trades at $58.75 (market cap $7.61B). The key difference: Marriott International Inc is far larger — about 12× 10X Genomics Inc's market cap, and Marriott International Inc pays a 0.84% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| MAR | TXG | |
|---|---|---|
Market Cap | $91.14B | $7.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $58.57 |
52-Week Low | $259.04 | $11.34 |
Enterprise Value | $108.45B | $7.14B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $348.44, down 1.55% on the day, with a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $3.19, beating estimates, but revenue growth faces headwinds. Key risks include high debt levels and valuation concerns, while analyst consensus remains positive with a $387.31 price target.
Outlook: MAR's fee-based model and loyalty program drive growth, but elevated P/E of 36.18 and rising debt-to-asset ratio warrant caution. Upside hinges on sustained RevPAR gains and effective cost management amid global economic uncertainty.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
